Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Effects of central dopaminergic blockade with pimozide upon the EEG stages of sleep in man

Effects of central dopaminergic blockade with pimozide upon the EEG stages of sleep in man 213 41 41 1 1 Teresa Sagalés Sergio Erill Servicio de Electroencefalografía y Neurofisiología Clínica Ciudad Sanitaria de la Seguridad Social Spain Departamento de Farmacología Universidad Autónoma de Barcelona Spain Abstract The effect of pimozide, a potent and specific blocker of central dopaminergic transmission, upon the sleep of man was studied in six healthy volunteers. Given at doses of 1 and 4 mg, which have clear central effects in humans, pimozide produced only minor changes in the EEG patterns of sleep. At these doses a slight and non-significant decrease in phase I sleep was observed, while phases W, II, III, IV and REM were not modified. No differences were noted between drug or post-treatment and control nights in total NREM sleep, total REM sleep, number of episodes of REM or total number of eye movements. An increase in REM sleep in the first third of the second pimozide night and an increase in the duration of the first REM period in the first drug night were the only statistically significant findings. If one accepts that central effects seen in man after pimozide given in conditions similar to those of this study are due to dopaminergic blockade, our results tend to suggest that dopamine is, at most, of rather minor importance in the physiology of sleep in man. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Psychopharmacology Springer Journals

Effects of central dopaminergic blockade with pimozide upon the EEG stages of sleep in man

Psychopharmacology , Volume 41 (1) – Jan 1, 1975

Loading next page...
 
/lp/springer-journals/effects-of-central-dopaminergic-blockade-with-pimozide-upon-the-eeg-I5oryJM6s2

References (23)

Publisher
Springer Journals
Copyright
Copyright © 1975 by Springer-Verlag
Subject
Biomedicine; Pharmacology/Toxicology; Psychiatry
ISSN
0033-3158
eISSN
1432-2072
DOI
10.1007/BF00421306
Publisher site
See Article on Publisher Site

Abstract

213 41 41 1 1 Teresa Sagalés Sergio Erill Servicio de Electroencefalografía y Neurofisiología Clínica Ciudad Sanitaria de la Seguridad Social Spain Departamento de Farmacología Universidad Autónoma de Barcelona Spain Abstract The effect of pimozide, a potent and specific blocker of central dopaminergic transmission, upon the sleep of man was studied in six healthy volunteers. Given at doses of 1 and 4 mg, which have clear central effects in humans, pimozide produced only minor changes in the EEG patterns of sleep. At these doses a slight and non-significant decrease in phase I sleep was observed, while phases W, II, III, IV and REM were not modified. No differences were noted between drug or post-treatment and control nights in total NREM sleep, total REM sleep, number of episodes of REM or total number of eye movements. An increase in REM sleep in the first third of the second pimozide night and an increase in the duration of the first REM period in the first drug night were the only statistically significant findings. If one accepts that central effects seen in man after pimozide given in conditions similar to those of this study are due to dopaminergic blockade, our results tend to suggest that dopamine is, at most, of rather minor importance in the physiology of sleep in man.

Journal

PsychopharmacologySpringer Journals

Published: Jan 1, 1975

There are no references for this article.